## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.7% in mid entry zone (3.0-6.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (0.1%) confirms momentum alignment. Outperforming sector by 3.3%. Caution: momentum weakening (-9.2% MRS), overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($60.17)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Arrowhead climbs to 52-week high as RNAi bets pay off**
- Source: Longevity.Technology | 20251215T170950 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals has experienced a dramatic turnaround in 2025, reaching a 52-week high after its RNA interference (RNAi) drug, Redemplo (plozasiran), received FDA approval for familial chylomicronemia syndrome (FCS) and Breakthrough Therapy designation for severe hypertriglyceridemia (SHTG). The company's stock has more than tripled in value over the past year, reflecting investor confidence in its validated RNAi platform, expanding pipeline into broader markets like Alzheimer's disease, and significant partnerships with major pharmaceutical companies. Despite ongoing patent litigation and clinical trial risks, Arrowhead's recent successes have solidified its position as a commercial-stage biotech player.

**2. Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress**
- Source: Simply Wall Street | 20251215T040950 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (ARWR) has seen significant clinical and regulatory progress with the FDA approval of REDEMPLO, Breakthrough Therapy status for plozasiran, and the advancement of ARO-MAPT into human trials. These developments have led to substantial share price increases, with the stock currently trading above analyst targets. Despite this positive momentum, Simply Wall St assesses the company as 22% overvalued with a fair value of $57.67, highlighting a debate over whether current growth is already priced in.

**3. 36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc**
- Source: MarketBeat | 20251215T110950 | Somewhat-Bullish | Relevance: 100%
- Marex Group plc recently acquired 36,469 shares of Arrowhead Pharmaceuticals, Inc. ($ARWR) during the second quarter, valued at approximately $576,000, bringing institutional ownership to about 62.61%. Analysts have a "Moderate Buy" consensus with an average price target of $58.56, but company insiders have been selling shares, reducing their ownership to 4.30%. The biotechnology company currently trades near $70 with a market capitalization around $9.5 billion.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($2.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.3%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +37%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -27% YoY, concerning. Analyst sentiment positive (8 raises, avg +37%). Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 13.9% to 4.7% (-9.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 81st percentile. MRS_5 at 0.1% confirms short-term momentum alignment. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.00), confirming momentum. RSI overbought at 72, risk of mean reversion. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.74% (CS: 82) | Strong |
| RSI_14 | 71.8 | Overbought |
| MACD Histogram | 1.00 | Bullish |
| vs SMA20 | 1.222x | Above |
| vs SMA50 | 1.498x | Above |
| vs SMA200 | 2.732x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $68.45
- **Stop Loss:** $60.17 (12.1% risk)
- **Target:** $80.87 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 144
- **Position Value:** $9,856.80
- **Portfolio %:** 9.86%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*